Riskpilot← Back to searchSign inGet full accessDermalant AB
ABActiveOrg 5590418793Klåva Gårdsväg 1 CMedical specialists activities · NACE 8622Est. 20151 employees
Revenue 2025
SEK 181K
-78% vs 2024
EBITDA margin
-0.3%
-100% vs 2024
Equity ratio
99.8%
Financial strength
Net profit 2025
SEK 3K
-99% vs 2024
| Revenue | SEK 181K | -78% |
| EBITDA | SEK -557 | -100% |
| Net profit | SEK 3K | -99% |
| Total assets | SEK 6,5M | -4% |
| Equity | SEK 6,4M | -3% |
| Employees | 1 | — |
Legal name
Dermalant AB
Org number
5590418793
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
15 december 2015
Share capital
SEK 50 000
Employees
1 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Firman tecknas var för sig av ledamoten suppleanten Dessutom har verkställande direktören rätt att teckna firmanbeträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall bedriva specialistläkarvård inom hälso- och sjukvård, uthyrning av läkare, kosmetisk och medicinsk hälso- och sjukvård inom sjukhus och privatmottagningar och därmed förenlig verksamhet.
Address
Klåva Gårdsväg 1 C
Email
dermalant@yahoo.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 2 951 | 1 573 | 1 526 | 814 | 181 |
| Staff expenses | — | −812 | −720 | −475 | −136 |
| EBITDA | 1 990 | 680 | 687 | 260 | −1 |
| Depreciation & amort. | −0 | — | — | — | — |
| EBIT | 1 990 | 680 | 687 | 260 | −1 |
| Net financials | −3 | −0 | 1 | 91 | 3 |
| Profit before tax | 1 988 | 680 | 688 | 351 | 3 |
| Tax | −427 | −142 | −142 | −73 | — |
| Net profit | 1 561 | 538 | 546 | 279 | 3 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 5 679 | 6 421 | 6 689 | 6 690 | 6 452 |
| Equity | 5 342 | 6 210 | 6 556 | 6 634 | 6 437 |
| Long-term debt | 0 | — | 0 | — | — |
| Short-term debt | 325 | 212 | 134 | 56 | 15 |
| Total debt | 325 | 212 | 134 | 56 | 15 |
EBITDA margin
-0.3%
This company
15.8%
Market median
-102% vs market
20212025
Equity ratio
99.8%
This company
38.2%
Market median
+161% vs market
20212025
Return on equity
0.0%
This company
18.4%
Market median
-100% vs market
20212025
Net profit margin
1.6%
This company
8.1%
Market median
-80% vs market
20212025
Asset turnover
0.03×
This company
1.12×
Market median
-97% vs market
20212025
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AN Chief Executive Officer | Chief Executive Officer | 2022 |
AN Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2021 | |
| Board of Directors | 2021 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Dermalant AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Athina Ntinti | Chief Executive Officer | 0 companies |
| Athina Ntinti | Chief Executive Officer | 0 companies |
| Argyro Kyriazidou | Deputy Board Member | 0 companies |
| Lampros Ntintis | Board of Directors | 0 companies |